← 產業報告目錄
PD-1&PD-L1 Immunotherapy Industry Research Report 2026
出版商 APO Research產業別 Healthcare & Life Sciences出版日期 2026-01-02頁數 123報告編號 APO-807cec76de
授權報價
| Single User | $2,950 USD |
| Multi User | $4,430 USD |
| Enterprise | $5,900 USD |
報告摘要
The global PD-1&PD-L1 Immunotherapy market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for PD-1&PD-L1 Immunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for PD-1&PD-L1 Immunotherapy is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
The Asia Pacific market for PD-1&PD-L1 Immunotherapy is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of PD-1&PD-L1 Immunotherapy include Sanofi S.A., Novartis AG, Merck & Co., Inc., Eli Lilly & Company, Pfizer Inc., Jiangsu HengRui Medicine Co., Ltd., GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc. and Innovent Biologics, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global PD-1&PD-L1 Immunotherapy market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
PD-1&PD-L1 Immunotherapy Market by Company
Sanofi S.A.
Novartis AG
Merck & Co., Inc.
Eli Lilly & Company
Pfizer Inc.
Jiangsu HengRui Medicine Co., Ltd.
GlaxoSmithKline plc
Regeneron Pharmaceuticals Inc.
Innovent Biologics, Inc.
F. Hoffmann-La Roche Ltd
Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
Bristol-Myers Squibb Company
BeiGene, Ltd.
AstraZeneca Plc
PD-1&PD-L1 Immunotherapy Segment by Type
PD-1 Inhibitors
PD-L1 Inhibitors
PD-1&PD-L1 Immunotherapy Segment by Application
Non-Small Cell Lung Cancer
Hepatocellular Carcinoma
Urothelial Carcinoma
Esophageal Cancer
Small Cell Lung Cancer
Others
PD-1&PD-L1 Immunotherapy Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-1&PD-L1 Immunotherapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PD-1&PD-L1 Immunotherapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-1&PD-L1 Immunotherapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of PD-1&PD-L1 Immunotherapy manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of PD-1&PD-L1 Immunotherapy by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of PD-1&PD-L1 Immunotherapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
目錄 Table of Contents
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global PD-1&PD-L1 Immunotherapy Market Size (2021-2032)
2.2.2 Global PD-1&PD-L1 Immunotherapy Sales (2021-2032)
2.2.3 Global PD-1&PD-L1 Immunotherapy Market Average Price (2021-2032)
2.3 PD-1&PD-L1 Immunotherapy by Type
2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
2.3.2 PD-1 Inhibitors
2.3.3 PD-L1 Inhibitors
2.4 PD-1&PD-L1 Immunotherapy by Application
2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
2.4.2 Non-Small Cell Lung Cancer
2.4.3 Hepatocellular Carcinoma
2.4.4 Urothelial Carcinoma
2.4.5 Esophageal Cancer
2.4.6 Small Cell Lung Cancer
2.4.7 Others
3 Market Competitive Landscape by Manufacturers
3.1 Global PD-1&PD-L1 Immunotherapy Market Competitive Situation by Manufacturers (2021 Versus 2025)
3.2 Global PD-1&PD-L1 Immunotherapy Sales (K Units) of Manufacturers (2021-2026)
3.3 Global PD-1&PD-L1 Immunotherapy Revenue of Manufacturers (2021-2026)
3.4 Global PD-1&PD-L1 Immunotherapy Average Price by Manufacturers (2021-2026)
3.5 Global PD-1&PD-L1 Immunotherapy Industry Ranking, 2024 VS 2025 VS 2026
3.6 Global Manufacturers of PD-1&PD-L1 Immunotherapy, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of PD-1&PD-L1 Immunotherapy, Product Type & Application
3.8 Global Manufacturers of PD-1&PD-L1 Immunotherapy, Established Date
3.9 Global PD-1&PD-L1 Immunotherapy Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Sanofi S.A.
4.1.1 Sanofi S.A. Company Information
4.1.2 Sanofi S.A. Business Overview
4.1.3 Sanofi S.A. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2021-2026)
4.1.4 Sanofi S.A. PD-1&PD-L1 Immunotherapy Product Portfolio
4.1.5 Sanofi S.A. Recent Developments
4.2 Novartis AG
4.2.1 Novartis AG Company Information
4.2.2 Novartis AG Business Overview
4.2.3 Novartis AG PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2021-2026)
4.2.4 Novartis AG PD-1&PD-L1 Immunotherapy Product Portfolio
4.2.5 Novartis AG Recent Developments
4.3 Merck & Co., Inc.
4.3.1 Merck & Co., Inc. Company Information
4.3.2 Merck & Co., Inc. Business Overview
4.3.3 Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2021-2026)
4.3.4 Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
4.3.5 Merck & Co., Inc. Recent Developments
4.4 Eli Lilly & Company
4.4.1 Eli Lilly & Company Company Information
4.4.2 Eli Lilly & Company Business Overview
4.4.3 Eli Lilly & Company PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2021-2026)
4.4.4 Eli Lilly & Company PD-1&PD-L1 Immunotherapy Product Portfolio
4.4.5 Eli Lilly & Company Recent Developments
4.5 Pfizer Inc.
4.5.1 Pfizer Inc. Company Information
4.5.2 Pfizer Inc. Business Overview
4.5.3 Pfizer Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2021-2026)
4.5.4 Pfizer Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
4.5.5 Pfizer Inc. Recent Developments
4.6 Jiangsu HengRui Medicine Co., Ltd.
4.6.1 Jiangsu HengRui Medicine Co., Ltd. Company Information
4.6.2 Jiangsu HengRui Medicine Co., Ltd. Business Overview
4.6.3 Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2021-2026)
4.6.4 Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio
4.6.5 Jiangsu HengRui Medicine Co., Ltd. Recent Developments
4.7 GlaxoSmithKline plc
4.7.1 GlaxoSmithKline plc Company Information
4.7.2 GlaxoSmithKline plc Business Overview
4.7.3 GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2021-2026)
4.7.4 GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Product Portfolio
4.7.5 GlaxoSmithKline plc Recent Developments
4.8 Regeneron Pharmaceuticals Inc.
4.8.1 Regeneron Pharmaceuticals Inc. Company Information
4.8.2 Regeneron Pharmaceuticals Inc. Business Overview
4.8.3 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2021-2026)
4.8.4 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
4.8.5 Regeneron Pharmaceuticals Inc. Recent Developments
4.9 Innovent Biologics, Inc.
4.9.1 Innovent Biologics, Inc. Company Information
4.9.2 Innovent Biologics, Inc. Business Overview
4.9.3 Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2021-2026)
4.9.4 Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
4.9.5 Innovent Biologics, Inc. Recent Developments
4.10 F. Hoffmann-La Roche Ltd
4.10.1 F. Hoffmann-La Roche Ltd Company Information
4.10.2 F. Hoffmann-La Roche Ltd Business Overview
4.10.3 F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2021-2026)
4.10.4 F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Product Portfolio
4.10.5 F. Hoffmann-La Roche Ltd Recent Developments
4.11 Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
4.11.1 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Company Information
4.11.2 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Business Overview
4.11.3 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2021-2026)
4.11.4 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio
4.11.5 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Recent Developments
4.12 Bristol-Myers Squibb Company
4.12.1 Bristol-Myers Squibb Company Company Information
4.12.2 Bristol-Myers Squibb Company Business Overview
4.12.3 Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2021-2026)
4.12.4 Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Product Portfolio
4.12.5 Bristol-Myers Squibb Company Recent Developments
4.13 BeiGene, Ltd.
4.13.1 BeiGene, Ltd. Company Information
4.13.2 BeiGene, Ltd. Business Overview
4.13.3 BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2021-2026)
4.13.4 BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio
4.13.5 BeiGene, Ltd. Recent Developments
4.14 AstraZeneca Plc
4.14.1 AstraZeneca Plc Company Information
4.14.2 AstraZeneca Plc Business Overview
4.14.3 AstraZeneca Plc PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2021-2026)
4.14.4 AstraZeneca Plc PD-1&PD-L1 Immunotherapy Product Portfolio
4.14.5 AstraZeneca Plc Recent Developments
5 Global PD-1&PD-L1 Immunotherapy Market Scenario by Region
5.1 Global PD-1&PD-L1 Immunotherapy Market Size by Region: 2021 VS 2025 VS 2032
5.2 Global PD-1&PD-L1 Immunotherapy Sales by Region: 2021-2032
5.2.1 Global PD-1&PD-L1 Immunotherapy Sales by Region: 2021-2026
5.2.2 Global PD-1&PD-L1 Immunotherapy Sales by Region: 2027-2032
5.3 Global PD-1&PD-L1 Immunotherapy Revenue by Region: 2021-2032
5.3.1 Global PD-1&PD-L1 Immunotherapy Revenue by Region: 2021-2026
5.3.2 Global PD-1&PD-L1 Immunotherapy Revenue by Region: 2027-2032
5.4 North America PD-1&PD-L1 Immunotherapy Market Facts & Figures by Country
5.4.1 North America PD-1&PD-L1 Immunotherapy Market Size by Country: 2021 VS 2025 VS 2032
5.4.2 North America PD-1&PD-L1 Immunotherapy Sales by Country (2021-2032)
5.4.3 North America PD-1&PD-L1 Immunotherapy Revenue by Country (2021-2032)
5.4.4 United States
5.4.5 Canada
5.5 Europe PD-1&PD-L1 Immunotherapy Market Facts & Figures by Country
5.5.1 Europe PD-1&PD-L1 Immunotherapy Market Size by Country: 2021 VS 2025 VS 2032
5.5.2 Europe PD-1&PD-L1 Immunotherapy Sales by Country (2021-2032)
5.5.3 Europe PD-1&PD-L1 Immunotherapy Revenue by Country (2021-2032)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Netherlands
5.6 Asia Pacific PD-1&PD-L1 Immunotherapy Market Facts & Figures by Country
5.6.1 Asia Pacific PD-1&PD-L1 Immunotherapy Market Size by Country: 2021 VS 2025 VS 2032
5.6.2 Asia Pacific PD-1&PD-L1 Immunotherapy Sales by Country (2021-2032)
5.6.3 Asia Pacific PD-1&PD-L1 Immunotherapy Revenue by Country (2021-2032)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Southeast Asia
5.7 South America PD-1&PD-L1 Immunotherapy Market Facts & Figures by Country
5.7.1 South America PD-1&PD-L1 Immunotherapy Market Size by Country: 2021 VS 2025 VS 2032
5.7.2 South America PD-1&PD-L1 Immunotherapy Sales by Country (2021-2032)
5.7.3 South America PD-1&PD-L1 Immunotherapy Revenue by Country (2021-2032)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa PD-1&PD-L1 Immunotherapy Market Facts & Figures by Country
5.8.1 Middle East and Africa PD-1&PD-L1 Immunotherapy Market Size by Country: 2021 VS 2025 VS 2032
5.8.2 Middle East and Africa PD-1&PD-L1 Immunotherapy Sales by Country (2021-2032)
5.8.3 Middle East and Africa PD-1&PD-L1 Immunotherapy Revenue by Country (2021-2032)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global PD-1&PD-L1 Immunotherapy Sales by Type (2021-2032)
6.1.1 Global PD-1&PD-L1 Immunotherapy Sales by Type (2021-2032) & (K Units)
6.1.2 Global PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2021-2032)
6.2 Global PD-1&PD-L1 Immunotherapy Revenue by Type (2021-2032)
6.2.1 Global PD-1&PD-L1 Immunotherapy Sales by Type (2021-2032) & (US$ Million)
6.2.2 Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2021-2032)
6.3 Global PD-1&PD-L1 Immunotherapy Price by Type (2021-2032)
7 Segment by Application
7.1 Global PD-1&PD-L1 Immunotherapy Sales by Application (2021-2032)
7.1.1 Global PD-1&PD-L1 Immunotherapy Sales by Application (2021-2032) & (K Units)
7.1.2 Global PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2021-2032)
7.2 Global PD-1&PD-L1 Immunotherapy Revenue by Application (2021-2032)
7.2.1 Global PD-1&PD-L1 Immunotherapy Sales by Application (2021-2032) & (US$ Million)
7.2.2 Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2021-2032)
7.3 Global PD-1&PD-L1 Immunotherapy Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
8.1 PD-1&PD-L1 Immunotherapy Value Chain Analysis
8.1.1 PD-1&PD-L1 Immunotherapy Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 PD-1&PD-L1 Immunotherapy Production Mode & Process
8.2 PD-1&PD-L1 Immunotherapy Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 PD-1&PD-L1 Immunotherapy Distributors
8.2.3 PD-1&PD-L1 Immunotherapy Customers
9 Global PD-1&PD-L1 Immunotherapy Analyzing Market Dynamics
9.1 PD-1&PD-L1 Immunotherapy Industry Trends
9.2 PD-1&PD-L1 Immunotherapy Industry Drivers
9.3 PD-1&PD-L1 Immunotherapy Industry Opportunities and Challenges
9.4 PD-1&PD-L1 Immunotherapy Industry Restraints
10 Report Conclusion
11 Disclaimer
圖表清單 List of Tables & Figures
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 5. Global PD-1&PD-L1 Immunotherapy Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
Table 6. Global PD-1&PD-L1 Immunotherapy Sales (K Units) of Manufacturers (2021-2026)
Table 7. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Manufacturers (2021-2026)
Table 8. Global PD-1&PD-L1 Immunotherapy Revenue of Manufacturers (2021-2026)
Table 9. Global PD-1&PD-L1 Immunotherapy Revenue Share by Manufacturers (2021-2026)
Table 10. Global Market PD-1&PD-L1 Immunotherapy Average Price (US$/Unit) of Manufacturers (2021-2026)
Table 11. Global PD-1&PD-L1 Immunotherapy Industry Ranking, 2024 VS 2025 VS 2026
Table 12. Global Manufacturers of PD-1&PD-L1 Immunotherapy, Manufacturing Sites & Headquarters
Table 13. Global Manufacturers of PD-1&PD-L1 Immunotherapy, Product Type & Application
Table 14. Global PD-1&PD-L1 Immunotherapy Manufacturers Established Date
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global PD-1&PD-L1 Immunotherapy by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 18. Sanofi S.A. Company Information
Table 19. Sanofi S.A. Business Overview
Table 20. Sanofi S.A. PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 21. Sanofi S.A. PD-1&PD-L1 Immunotherapy Product Portfolio
Table 22. Sanofi S.A. Recent Developments
Table 23. Novartis AG Company Information
Table 24. Novartis AG Business Overview
Table 25. Novartis AG PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 26. Novartis AG PD-1&PD-L1 Immunotherapy Product Portfolio
Table 27. Novartis AG Recent Developments
Table 28. Merck & Co., Inc. Company Information
Table 29. Merck & Co., Inc. Business Overview
Table 30. Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 31. Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
Table 32. Merck & Co., Inc. Recent Developments
Table 33. Eli Lilly & Company Company Information
Table 34. Eli Lilly & Company Business Overview
Table 35. Eli Lilly & Company PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 36. Eli Lilly & Company PD-1&PD-L1 Immunotherapy Product Portfolio
Table 37. Eli Lilly & Company Recent Developments
Table 38. Pfizer Inc. Company Information
Table 39. Pfizer Inc. Business Overview
Table 40. Pfizer Inc. PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 41. Pfizer Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
Table 42. Pfizer Inc. Recent Developments
Table 43. Jiangsu HengRui Medicine Co., Ltd. Company Information
Table 44. Jiangsu HengRui Medicine Co., Ltd. Business Overview
Table 45. Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 46. Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio
Table 47. Jiangsu HengRui Medicine Co., Ltd. Recent Developments
Table 48. GlaxoSmithKline plc Company Information
Table 49. GlaxoSmithKline plc Business Overview
Table 50. GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 51. GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Product Portfolio
Table 52. GlaxoSmithKline plc Recent Developments
Table 53. Regeneron Pharmaceuticals Inc. Company Information
Table 54. Regeneron Pharmaceuticals Inc. Business Overview
Table 55. Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 56. Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
Table 57. Regeneron Pharmaceuticals Inc. Recent Developments
Table 58. Innovent Biologics, Inc. Company Information
Table 59. Innovent Biologics, Inc. Business Overview
Table 60. Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 61. Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
Table 62. Innovent Biologics, Inc. Recent Developments
Table 63. F. Hoffmann-La Roche Ltd Company Information
Table 64. F. Hoffmann-La Roche Ltd Business Overview
Table 65. F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 66. F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Product Portfolio
Table 67. F. Hoffmann-La Roche Ltd Recent Developments
Table 68. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Company Information
Table 69. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Business Overview
Table 70. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 71. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio
Table 72. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Recent Developments
Table 73. Bristol-Myers Squibb Company Company Information
Table 74. Bristol-Myers Squibb Company Business Overview
Table 75. Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Product Portfolio
Table 77. Bristol-Myers Squibb Company Recent Developments
Table 78. BeiGene, Ltd. Company Information
Table 79. BeiGene, Ltd. Business Overview
Table 80. BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio
Table 82. BeiGene, Ltd. Recent Developments
Table 83. AstraZeneca Plc Company Information
Table 84. AstraZeneca Plc Business Overview
Table 85. AstraZeneca Plc PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. AstraZeneca Plc PD-1&PD-L1 Immunotherapy Product Portfolio
Table 87. AstraZeneca Plc Recent Developments
Table 88. Global PD-1&PD-L1 Immunotherapy Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Table 89. Global PD-1&PD-L1 Immunotherapy Sales by Region (2021-2026) & (K Units)
Table 90. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Region (2021-2026)
Table 91. Global PD-1&PD-L1 Immunotherapy Sales by Region (2027-2032) & (K Units)
Table 92. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Region (2027-2032)
Table 93. Global PD-1&PD-L1 Immunotherapy Revenue by Region (2021-2026) & (US$ Million)
Table 94. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Region (2021-2026)
Table 95. Global PD-1&PD-L1 Immunotherapy Revenue by Region (2027-2032) & (US$ Million)
Table 96. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Region (2027-2032)
Table 97. North America PD-1&PD-L1 Immunotherapy Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 98. North America PD-1&PD-L1 Immunotherapy Sales by Country (2021-2026) & (K Units)
Table 99. North America PD-1&PD-L1 Immunotherapy Sales by Country (2027-2032) & (K Units)
Table 100. North America PD-1&PD-L1 Immunotherapy Revenue by Country (2021-2026) & (US$ Million)
Table 101. North America PD-1&PD-L1 Immunotherapy Revenue by Country (2027-2032) & (US$ Million)
Table 102. Europe PD-1&PD-L1 Immunotherapy Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 103. Europe PD-1&PD-L1 Immunotherapy Sales by Country (2021-2026) & (K Units)
Table 104. Europe PD-1&PD-L1 Immunotherapy Sales by Country (2027-2032) & (K Units)
Table 105. Europe PD-1&PD-L1 Immunotherapy Revenue by Country (2021-2026) & (US$ Million)
Table 106. Europe PD-1&PD-L1 Immunotherapy Revenue by Country (2027-2032) & (US$ Million)
Table 107. Asia Pacific PD-1&PD-L1 Immunotherapy Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 108. Asia Pacific PD-1&PD-L1 Immunotherapy Sales by Country (2021-2026) & (K Units)
Table 109. Asia Pacific PD-1&PD-L1 Immunotherapy Sales by Country (2027-2032) & (K Units)
Table 110. Asia Pacific PD-1&PD-L1 Immunotherapy Revenue by Country (2021-2026) & (US$ Million)
Table 111. Asia Pacific PD-1&PD-L1 Immunotherapy Revenue by Country (2027-2032) & (US$ Million)
Table 112. South America PD-1&PD-L1 Immunotherapy Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 113. South America PD-1&PD-L1 Immunotherapy Sales by Country (2021-2026) & (K Units)
Table 114. South America PD-1&PD-L1 Immunotherapy Sales by Country (2027-2032) & (K Units)
Table 115. South America PD-1&PD-L1 Immunotherapy Revenue by Country (2021-2026) & (US$ Million)
Table 116. South America PD-1&PD-L1 Immunotherapy Revenue by Country (2027-2032) & (US$ Million)
Table 117. Middle East and Africa PD-1&PD-L1 Immunotherapy Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 118. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales by Country (2021-2026) & (K Units)
Table 119. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales by Country (2027-2032) & (K Units)
Table 120. Middle East and Africa PD-1&PD-L1 Immunotherapy Revenue by Country (2021-2026) & (US$ Million)
Table 121. Middle East and Africa PD-1&PD-L1 Immunotherapy Revenue by Country (2027-2032) & (US$ Million)
Table 122. Global PD-1&PD-L1 Immunotherapy Sales by Type (2021-2026) & (K Units)
Table 123. Global PD-1&PD-L1 Immunotherapy Sales by Type (2027-2032) & (K Units)
Table 124. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2021-2026)
Table 125. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2027-2032)
Table 126. Global PD-1&PD-L1 Immunotherapy Revenue by Type (2021-2026) & (US$ Million)
Table 127. Global PD-1&PD-L1 Immunotherapy Revenue by Type (2027-2032) & (US$ Million)
Table 128. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2021-2026)
Table 129. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2027-2032)
Table 130. Global PD-1&PD-L1 Immunotherapy Price by Type (2021-2026) & (US$/Unit)
Table 131. Global PD-1&PD-L1 Immunotherapy Price by Type (2027-2032) & (US$/Unit)
Table 132. Global PD-1&PD-L1 Immunotherapy Sales by Application (2021-2026) & (K Units)
Table 133. Global PD-1&PD-L1 Immunotherapy Sales by Application (2027-2032) & (K Units)
Table 134. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2021-2026)
Table 135. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2027-2032)
Table 136. Global PD-1&PD-L1 Immunotherapy Revenue by Application (2021-2026) & (US$ Million)
Table 137. Global PD-1&PD-L1 Immunotherapy Revenue by Application (2027-2032) & (US$ Million)
Table 138. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2021-2026)
Table 139. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2027-2032)
Table 140. Global PD-1&PD-L1 Immunotherapy Price by Application (2021-2026) & (US$/Unit)
Table 141. Global PD-1&PD-L1 Immunotherapy Price by Application (2027-2032) & (US$/Unit)
Table 142. Key Raw Materials
Table 143. Raw Materials Key Suppliers
Table 144. PD-1&PD-L1 Immunotherapy Distributors List
Table 145. PD-1&PD-L1 Immunotherapy Customers List
Table 146. PD-1&PD-L1 Immunotherapy Industry Trends
Table 147. PD-1&PD-L1 Immunotherapy Industry Drivers
Table 148. PD-1&PD-L1 Immunotherapy Industry Restraints
Table 149. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. PD-1&PD-L1 Immunotherapy Product Image
Figure 5. Global PD-1&PD-L1 Immunotherapy Revenue (US$ Million), 2021 VS 2025 VS 2032
Figure 6. Global PD-1&PD-L1 Immunotherapy Market Size (2021-2032) & (US$ Million)
Figure 7. Global PD-1&PD-L1 Immunotherapy Sales (2021-2032) & (K Units)
Figure 8. Global PD-1&PD-L1 Immunotherapy Average Price (US$/Unit) & (2021-2032)
Figure 9. PD-1 Inhibitors Product Image
Figure 10. PD-L1 Inhibitors Product Image
Figure 11. Non-Small Cell Lung Cancer Product Image
Figure 12. Hepatocellular Carcinoma Product Image
Figure 13. Urothelial Carcinoma Product Image
Figure 14. Esophageal Cancer Product Image
Figure 15. Small Cell Lung Cancer Product Image
Figure 16. Others Product Image
Figure 17. Global PD-1&PD-L1 Immunotherapy Revenue Share by Manufacturers in 2025
Figure 18. Global Manufacturers of PD-1&PD-L1 Immunotherapy, Manufacturing Sites & Headquarters
Figure 19. Global Top 5 and 10 PD-1&PD-L1 Immunotherapy Players Market Share by Revenue in 2025
Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 21. Global PD-1&PD-L1 Immunotherapy Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Figure 22. Global PD-1&PD-L1 Immunotherapy Sales by Region in 2025
Figure 23. Global PD-1&PD-L1 Immunotherapy Revenue by Region in 2025
Figure 24. North America PD-1&PD-L1 Immunotherapy Market Size by Country in 2025
Figure 25. North America PD-1&PD-L1 Immunotherapy Sales Market Share by Country (2021-2032)
Figure 26. North America PD-1&PD-L1 Immunotherapy Revenue Market Share by Country (2021-2032)
Figure 27. United States PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 28. Canada PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 29. Europe PD-1&PD-L1 Immunotherapy Market Size by Country in 2025
Figure 30. Europe PD-1&PD-L1 Immunotherapy Sales Market Share by Country (2021-2032)
Figure 31. Europe PD-1&PD-L1 Immunotherapy Revenue Market Share by Country (2021-2032)
Figure 32. Germany PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 33. France PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 34. U.K. PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 35. Italy PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 36. Netherlands PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 37. Asia Pacific PD-1&PD-L1 Immunotherapy Market Size by Country in 2025
Figure 38. Asia Pacific PD-1&PD-L1 Immunotherapy Sales Market Share by Country (2021-2032)
Figure 39. Asia Pacific PD-1&PD-L1 Immunotherapy Revenue Market Share by Country (2021-2032)
Figure 40. China PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 41. Japan PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 42. South Korea PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 43. India PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 44. Australia PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 45. China Taiwan PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 46. Southeast Asia PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 47. Southeast Asia PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 48. South America PD-1&PD-L1 Immunotherapy Market Size by Country in 2025
Figure 49. South America PD-1&PD-L1 Immunotherapy Sales Market Share by Country (2021-2032)
Figure 50. South America PD-1&PD-L1 Immunotherapy Revenue Market Share by Country (2021-2032)
Figure 51. Mexico PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 52. Brazil PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 53. Argentina PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 54. Middle East and Africa PD-1&PD-L1 Immunotherapy Market Size by Country in 2025
Figure 55. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales Market Share by Country (2021-2032)
Figure 56. Middle East and Africa PD-1&PD-L1 Immunotherapy Revenue Market Share by Country (2021-2032)
Figure 57. Turkey PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 58. Saudi Arabia PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 59. UAE PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 60. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2021-2032)
Figure 61. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2021-2032)
Figure 62. Global PD-1&PD-L1 Immunotherapy Price (US$/Unit) by Type (2021-2032)
Figure 63. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2021-2032)
Figure 64. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2021-2032)
Figure 65. Global PD-1&PD-L1 Immunotherapy Price (US$/Unit) by Application (2021-2032)
Figure 66. PD-1&PD-L1 Immunotherapy Value Chain
Figure 67. PD-1&PD-L1 Immunotherapy Production Mode & Process
Figure 68. Direct Comparison with Distribution Share
Figure 69. Distributors Profiles
Figure 70. PD-1&PD-L1 Immunotherapy Industry Opportunities and Challenges
提及公司
Sanofi S.A.Novartis AGMerck & Co., Inc.Eli Lilly & CompanyPfizer Inc.Jiangsu HengRui Medicine Co., Ltd.GlaxoSmithKline plcRegeneron Pharmaceuticals Inc.Innovent Biologics, Inc.F. Hoffmann-La Roche LtdChia Tai Tianqing Pharmaceutical Group Co. Ltd.Bristol-Myers Squibb CompanyBeiGene, Ltd.AstraZeneca Plc
量子訊息有限公司為 APO Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們